Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment

• Status: Terminated
• Trial end date: 2020-02-03
• Target enrollment: 0
• Participant gender: All

Summary

To perform a study that investigates the effectiveness of adding the SGLT2 inhibitor dapagliflozin + the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin vs placebo to revert from a BBIT regimen to a BOT regimen in patients with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Tuebingen
• Treatments: Dapagliflozin; Saxagliptin

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Age 18 - 75 years

• Anti-GAD antibodies negative (Glutamic Acid Decarboxylase)

• C-peptide levels ≥ 1.5 ng/mL

• Fasting blood glucose > 126 mg/dl

• HbA1c 8.0 - 10.5 %

• BMI 25.0 - 45.0 kg/m2

• Previous therapy with BBIT (basal insulin and at least once daily bolus insulin)

Exclusion Criteria:

• Use of any oral antidiabetic treatment except for metformin (i.e., sulphonylureas, DPP-IV inhibitors, thiazolidinediones, SGLT-2 inhibitors (Sodium dependent glucose transporter) or GLP-1 analogues (glucagone like peptide) within the last three months prior to Screening

• Repeated episodes of severe hypoglycaemia within the last six months prior to Screening

• History of diabetic ketoacidosis, precoma diabetica, or diabetic coma

• Treatment with any other investigational drug within the last three months before Screening

• Acute infections within the last four weeks prior to Screening

• Recurrent urogenital infections

• History of pancreatitis

• Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures

• History of severe or multiple allergies

• Concomitant participation in other clinical trials

• Type 1 diabetes

• Cardiovascular disease Clinically relevant ventricular tachycardia or ventricular fibrillation, 3rd degree AV block or Torsades de Pointes or treatment with antiarrhythmic drugs. Percutaneous coronary intervention within the past 6 months. Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery; unstable angina; or stroke.

Uncontrolled unstable angina pectoris or history of pericarditis, myocarditis, endocarditis. Congestive heart failure NYHA (New York Heart Association) class III or IV. Increased risk of thromboembolism, e.g. subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.

• Malignancy including leukemia and lymphoma within the last 5y.

• Liver disease such as cirrhosis or chronic active hepatitis.

• Significant renal dysfunction (see also exclusion criteria laboratory abnormalities).

• State after kidney transplantation

• Endocrine disease:

Acromegaly or treatment with growth hormone or similar drugs. Chronic oral or parenteral corticosteroid treatment (>7 consecutive days of treatment) within 8 weeks; thyroid hormone replacement is allowed if the dosage has been stable for at least 3 months and the TSH is within normal limits

•Any of the following significant laboratory abnormalities: eGFR (as calculated by the MDRD equation) < 60 ml/min at Screening Fasting triglycerides >700 mg/dl (>7.9 mmol/l)

• Systolic blood pressure outside the range of 100-160 mmHg or diastolic blood pressure above 95 mmHg at Screening

• History of active substance abuse (including alcohol > 40g/day) within the past 2 years.

• Pregnancy or childbearing potential without adequate contraception

• Present therapy with systemic steroids

• Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI´s (selective serotonin reuptake inhibitor)

• Potentially unreliable subjects, and those judged by the investigator to be unsuitable for the study.

• Contraindications for Magnetic resonance (MR) scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia